Document is current

Article History

Received: 24 September 2024

Accepted: 7 November 2024

First Online: 2 December 2024

Declarations

:

: Thomas Danne has received speaker fees and research support from or has consulted for Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, Medtronic, Novo Nordisk, Provention Bio, Roche, Sanofi, and Vertex and is a shareholder of DreaMed Ltd. Stefan Gölz has received speaker fees and research support from or has consulted for Abbott, Ascencia, Novo Nordisk, Novartis, Sanofi, Astra Zeneca, MSD, Berlin Chemia, Lilly, Boehringer Ingelheim, Johnson & Johnson, Medical Tribune, Dexcom, Roche, Menarini, Santis, EvivaMed. Julia Mader has received research support from A. Menarini Diagnostics, Novo Nordisk, Sanofi; Advisory Board: Abbott Diabetes Care, Becton–Dickinson/Embecta, Eli Lilly, Medtronic, Novo Nordisk, PharmaSens, Roche Diabetes Care, Sanofi, Viatris; speaker fees from Abbott Diabetes Care, A. Menarini Diagnostics, Becton Dickinson/Embecta, Boehringer-Ingelheim, Eli Lilly, MedTrust, Novo Nordisk, Roche Diabetes Care, Sanofi, Servier, Ypsomed; Shareholder of decide Clinical Software GmbH. Stefan Bilz has received speaker’s fees from or consulted for Amgen, Sanofi, Novartis, Bayer, Daiichi-Sankyo, Novo Nordisk; travel support from Novo Nordisk. Julia Kenzler is an employee of Sanofi-Aventis Deutschland GmbH.

: The study was conducted in accordance with the Helsinki Declaration of 1964. The study received approval from the institutional review board or ethics committee at each participating center. Approval reference numbers were BASEC-Nr. 2020-01997, F-2020-106, 32-605 ex 19/2. A formal written informed consent was obtained from all patients prior to their enrolment in the study. Permissions were obtained to use the DTSQ questionnaire in this study.